Mefcom Capital Markets Ltd ("Manager to the Buyback") has submitted to BSE a copy of Letter of Offer for the attention of the Equity Shareholders of Nureca Ltd ("Target Company").
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts more than Nifty Microcap 250 and 3.5 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Nureca Limited has launched a buyback of up to 5,80,000 equity shares (5.80% of total paid-up capital) at ₹330 per share, for an aggregate consideration of up to ₹19.14 crore. The buyback is being executed through the tender offer route on a proportionate basis, with the promoter group opting not to participate. The record date for eligibility was December 12, 2025, and the buyback window is open from December 18 to December 24, 2025. The buyback size represents 9.88% of paid-up capital and free reserves on a standalone basis, within the SEBI-prescribed 10% limit. Based on the small-shareholder threshold of ₹2 lakh market value equating to 672 shares, the implied closing market price on the record date was roughly ₹297, meaning the ₹330 buyback price carries an approximate premium of ~10.9% over the market.
Eligible shareholders get a chance to tender shares at a price above prevailing market levels, which is supportive for the stock in the short term. Post-buyback, the reduction in share count should also lift earnings per share, while the promoter non-participation means the float effectively shrinks, which is mildly positive for remaining holders.